Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Type 2 Diabetes
Phase NA
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The standard treatment for Type 2 diabetes involves management of the disease based on average of blood glucose control over the past few months. In this study, the investigators test for the participants' ability to produce insulin, which is the hormone that the body makes to control blood sugar levels. The body produces insulin in response to eating. The participants will drink a meal replacement shake, and then test the blood for levels of insulin produced over 2 hours. With blood tests taken five times over two hours, the investigators will measure the blood glucose (sugar), and insulin levels. This study will assess the differences in insulin produced in the participants and try to understand the reasons for these differences.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Dietary Supplement: Boost Original meal replacement shake — One bottle of Boost Original meal replacement shake.

Primary Outcomes

  • Pancreatic insulin production capacity (PIPC) represented by the participant's insulin and C-peptide levels after drinking the meal replacement shake. (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-06-24
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ottawa Hospital Research Institute
Principal Investigators:
  • Cathy Sun, MD MSc (PRINCIPAL_INVESTIGATOR) - Ottawa Hospital Research Institute
Contact Information
Study Contact:
Cathy Sun, MD MSc
613-738-8333
csun@toh.ca
Cathy J Sun, MD MSc
The Ottawa Hospital
Interventions
  • Dietary Supplement: Boost Original meal replacement shake — One bottle of Boost Original meal replacement shake.
Study Locations (1 sites)
The Ottawa Hospital, Ottawa, Ontario K1H7W9 Canada
Eligibility Criteria
Inclusion Criteria: 1. Consent provided 2. Age \>= 18 years. 3. Diagnosed as type 2 diabetes mellitus. 4. Not on insulin therapy. Exclusion Criteria: 1. Diagnosed as another form of diabetes mellitus. 2. Allergic to one or more ingredients in Boost meal replacement shake. 3. Unable to fast since midnight and attend in person for the morning protocol.
Conditions Low Birth Weight, Kangaroo Mother Care, ...
Phase NA
Enrollment 1908
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if extended admission to the Kangaroo Mother Care (KMC) ward helps to prevent postpartum depression in mothers of low birthweight infants in a low-resource setting whose newborns were admitted to the neonatal intensive care unit (NICU) more than standard of care KMC. The main questions it aims to answer are: * Does longer KMC decrease the incidence of postpartum depression in mothers of low birthweight infants in a low-resource setting? * Does longer KMC improve neurodevelopmental outcomes of low birthweight infants at 6, 12, and 18 months in a low-resource setting? * What are the barriers to practicing KMC in low birthweight infants following hospital discharge in a low-resource setting? * What is the prevalence of paternal depression in a low resource setting? * Is it cost effective to admit preterm mother-infant dyads to the KMC ward following NICU discharge? Researchers will compare (extended admission to the KMC ward) to (standard of care KMC) to see if extended KMC decreases PPD in mothers of preterm infants in low-resource settings. Participants (infants) will: * At time of discharge from the NICU, when clinically stable, spend either \< 2 days in the KMC ward with their mothers or spend longer in the KMC ward until discharge. * Return to clinic at routine follow-up visits (at 2 weeks and at 6-8 weeks) where mothers will be screened for postpartum depression and fathers will be screened for depression. * Return to clinic for neurodevelopmental screening at 6, 12, and 18 months where mothers will be screened for postpartum depression and perceived social support and fathers will be screened for depression.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Kangaroo mother care (KMC) support for > 2 days — Admission to the kangaroo mother care (KMC) ward with continued support of kangaroo mother care, breastfeeding, and preterm infant care for greater than 2 days prior to discharge home
  • Behavioral: Kangaroo mother care (KMC) support for < 2 days — Admission to the kangaroo mother care (KMC) ward with continued support of kangaroo mother care, breastfeeding, and preterm infant care for less than 2 days prior to discharge home

Primary Outcomes

  • Percentage of Mothers with Postpartum Depression (PPD) (8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-12-01
Completion: 2027-09-30
Eligibility
Age: 1 Day and older
Sex: ALL
Volunteers: false
Enrollment: 1908 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Alabama at Birmingham
Collaborators: University Teaching Hospital, Lusaka, Zambia, University of Zambia, University of Cincinnati, Centre for Infectious Disease Research in Zambia
Principal Investigators:
  • Albert Manasyan, MD, MPH (PRINCIPAL_INVESTIGATOR) - Centre for Infectious Disease Research in Zambia
Contact Information
Study Contact:
Albert Manasyan, MD, MPH
+260976448994
albert.manasyan@cidrz.org
J.Anitha Menon, MA, PhD
+260977846116
AnithaMenon316@gmail.com
Jyoti Lakhwani, MD
00260976247685
jyoti.lakhwani90@gmail.com
Women and Newborn Hospital - University Teaching Hospitals
Interventions
  • Behavioral: Kangaroo mother care (KMC) support for > 2 days — Admission to the kangaroo mother care (KMC) ward with continued support of kangaroo mother care, breastfeeding, and preterm infant care for greater than 2 days prior to discharge home
  • Behavioral: Kangaroo mother care (KMC) support for < 2 days — Admission to the kangaroo mother care (KMC) ward with continued support of kangaroo mother care, breastfeeding, and preterm infant care for less than 2 days prior to discharge home
Study Locations (1 sites)
Women and Newborn Hospital - University Teaching Hospitals, Lusaka, 10101 Zambia
Eligibility Criteria
Inclusion Criteria: -AIM #1-2 and #5 Newborns who are: 1. Birthweight between 1000-2000gm 2. Admitted to the Women and Newborn Hospital-University Teaching Hospital (WNH-UTH) Neonatal Intensive Care Unit (NICU) \>48hrs ago 3. Stable preterm eligible for receiving KMC at the KMC Ward And their mothers who are - 4\. 16+ years of age (Mother) 5\. Residing within Lusaka Province with no intensions to relocate in the coming 18 months * AIM #3 1. Parents (mothers and fathers) whose newborn has been enrolled in the study 2. Trusted family member or friend of the mother whose newborns is enrolled into the study 3. 16+ years of age (mothers and fathers) 4. 18+ years of age (family members) * AIM # 4: 1. Fathers whose newborn has been enrolled into the study 2. 16+ years of age Exclusion Criteria: * AIM #1-2 and #5 1. Mothers who are on treatment for depression and/or anxiety 2. Mothers who did not consent 3. Underage mothers (16-17 years of age) whose parent(s) has not provided consent for their participation in the study * AIM #3 1\) Family members of parents who do not consent to study participation * AIM # 4: 1. Fathers who are on treatment for depression and/or anxiety 2. Fathers who did not provide informed consent 3. Underage fathers (16-17 years of age) whose parent(s) has not provided consent for their participation in the study
Conditions Breast Cancer
Phase PHASE4
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if dapagliflozin drug has a cardioprotective effect against anthracyclines-induced cardiotoxicity. It will also learn about the safety of dapagliflozin drug. Aim of the study: Evaluate cardioprotective effect and safety of dapagliflozin against anthracyclines-induced cardiotoxicity. The main questions it aims to answer are: 1. Does the drug lower the cardiotoxicity which induced by anthracyclines? 2. What medical problems do participants have when taking dapagliflozin drug? Treatment 1. Anthracyclines by 4 cycles included doxorubicin 50-60 mg/m2 with cyclophosphamide 600 mg as a combination or epirubicin 90-100 mg/m2 with cyclophosphamide 600 mg as a combination. 2. Dapagliflozin 10 mg tablet orally, once daily. Started 7 days before the first cycle of anthracyclines till the end of last anthracyclines dose.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Drug: Dapagliflozin 10mg Tab — Dapagliflozin 10 mg tablet orally, once daily. Started 7 days before the first cycle of anthracyclines till the end of last anthracyclines dose. taken orally, once daily. Started from 5 to 7 days before the first cycle of anthracyclines till the end of last anthracycline dose.

Primary Outcomes

  • N-terminal pro-B-type natriuretic peptide (NT-pro BNP) testing (Baseline and after the last cycle of anthracyclines ( 0 and 2 to 3 months from baseline))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2024-09-10
Completion: 2026-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Helwan University
Contact Information
Study Contact:
Shimaa Nabil Abd elaziz Hassanein, bachelor
+201115817090
Shimaa.Nabil@pharm.helwan.edu.eg
Sara Mohamed Mohamed, Lecturer
+201016903404
Sara.abdel-motaleb@pharm.helwan.edu.eg
Shimaa N abdelaziz, bachelor
01115817090
Shimaa.Nabil@pharm.helwan.edu.eg
Al demerdash hospital at oncology departement
Interventions
  • Drug: Dapagliflozin 10mg Tab — Dapagliflozin 10 mg tablet orally, once daily. Started 7 days before the first cycle of anthracyclines till the end of last anthracyclines dose. taken orally, once daily. Started from 5 to 7 days before the first cycle of anthracyclines till the end of last anthracycline dose.
Study Locations (1 sites)
Al demerdash hospital at oncology departement, Cairo, Cairo Governorate 202 Egypt
Eligibility Criteria
Inclusion Criteria: 1. patients with pathologically proved invasive breast carcinoma. 2. Patients were indicated for anthracyclines containing adjuvant chemotherapy or new adjuvant anthracyclines. 3. Renal function (eGFR \> 30 mL/minute per 1.73 m2 ) 4. LVEF is more than 50 % 5. Age ≥ 18 and ≤ 60 years old Exclusion Criteria: 1. patients with any cardiac condition that contraindicate the use of anthracyclines, like heart failure, arrythmia, stroke and myocardial infarction. 2. Previous anthracycline-containing regimens and any cardiotoxic chemotherapy regimens 3. pregnant or breastfeeding patients 4. patients receiving any other cardiotoxic agents. 5. Patients with diabetic ketoacidosis or patients with type 1 diabetes mellitus. 6. Mediastinal irradiation including heart. 7. Refusal to sign the written informed consent.
Conditions Depression, Anxiety, Post-traumatic Stre...
Phase NA
Enrollment 400
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Conditions treated in intensive care units (ICUs) such as the acute respiratory distress syndrome (ARDS), congestive heart failure, COVID pneumonia, and sepsis are common. These can lead to high rates of depression, anxiety, and PTSD that worsen quality of life. Yet there are few effective strategies able to overcome barriers of limited access to mental health care. Even less is known about the experiences of patients from racially and ethnically minoritized populations because of they haven't been included well in past research. To address this problem, the investigators developed Blueprint, a mobile app that coaches people to use adaptive coping skills to self-manage their symptoms. The investigators found that it reduced depression symptoms and improved quality of life compared to placebo. To confirm these promising findings, the investigators are doing a formal test of Blueprint. The investigators will enroll 400 people who received ICU care from 4 hospitals (Duke, UCLA, Colorado, and Oregon). These patients will be randomized to receive either the Blueprint mobile app or a special Education Program mobile app the investigators developed. -both delivered through similar mobile app platforms. Our specific aims are to see which program improves symptoms better across 6 months of follow up. This project addresses national research priorities and could advance the field with a personalizable yet population-focused therapy that could be scaled broadly and efficiently to enhance mental health equity.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Triple

Interventions / Regimen

  • Behavioral: Blueprint — This is a mobile app-based adaptive coping skills intervention that lasts 1 month
  • Behavioral: Education program — This is a mobile app-based education program that lasts 1 month

Primary Outcomes

  • Hospital Anxiety and Depression Scale (HADS) (Baseline, 1 month, 3 months, and 6 months post-randomization)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-15
Completion: 2028-04-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Duke University
Collaborators: Oregon Health and Science University, University of Colorado, Denver, University of California, Los Angeles
Principal Investigators:
  • Christopher Cox (PRINCIPAL_INVESTIGATOR) - Professor of Medicine
Contact Information
Study Contact:
Christopher Cox
919-681-7232
christopher.cox@duke.edu
Kristy Johnson
kristy.johnson@duke.edu
Kristy Johnson
kristy.johnson@duke.edu
Duke University Medical Center
Interventions
  • Behavioral: Blueprint — This is a mobile app-based adaptive coping skills intervention that lasts 1 month
  • Behavioral: Education program — This is a mobile app-based education program that lasts 1 month
Study Locations (1 sites)
Duke University Medical Center, Durham, North Carolina 27710 United States
Eligibility Criteria
Inclusion Criteria Inclusion criteria present in the hospital 1. Adult (age ≥18) 2. Managed in an ICU or stepdown unit for ≥24 hours during the time inclusion criterion #3 is met 3. Serious acute cardiorespiratory condition, defined as ≥1 of the following: * mechanical ventilation via endotracheal tube for ≥4 hours * non-invasive ventilation (CPAP, BiPAP) for ≥4 hours in a 24-hour period provided for acute respiratory failure * new use of supplemental oxygen ≥6 liters per minute (or increase in baseline continuous oxygen) * use of vasopressors for shock of any etiology * use of inotropes for shock of any etiology * use of pulmonary vasodilators * use of aortic balloon pump or cardiac assist device for cardiogenic shock * use of diuretic intravenous drip * evidence of acute coronary ischemia (i.e., elevated troponin level, supporting EKG changes, unstable angina symptoms documented) * urgent cardiac catheterization 4. Cognitive status intact • No history of pre-existing significant cognitive impairment (e.g., dementia) as per medical chart 5. Absence of severe mental illness * Treatment for severe mental illness (e.g., psychosis, bipolar affective disorder, schizoaffective disorder, schizoid personality disorder, schizophrenia \[as per medical record\], hospitalization for any psychiatric disorder) within the 6 months preceding the current hospital admission * Evidence of poorly managed severe mental illness * No endorsement of suicidality at time of admission or informed consent 6. Functional fluency in English or Spanish (i.e., sufficient knowledge of English or Spanish to complete study tasks like watch videos, complete surveys) Inclusion criteria present after hospital discharge (i.e., at the time of arrival home after discharge from the hospital) 1\. Elevated baseline psychological distress symptoms, defined as a Hospital Anxiety and Distress Scale (HADS) total score ≥8 Exclusion Criteria Exclusion criteria present in the hospital 1. Active alcohol or drug abuse (e.g., admission for alcohol withdrawal, drug-related complication, positive toxicology screening at admission, endorsement of active addiction) 2. Anticipated complex medical needs after discharge that would be disruptive to intervention and follow up; for example: * Anticipated surgical procedures * Anticipated complex medical regiment (e.g., new chemotherapy, new dialysis, need for repeat surgery, pregnant and near term) * Plan for comfort care 3. Other complex needs anticipated that could interfere with the ability to complete study procedures. Examples include: * Anticipated disruptive travel * Inability to use mobile app * Anticipated unstable living situation 4. Anticipated or actual discharge to a location other than independent in a home setting (e.g., nursing home, long-term acute care facility, inpatient rehabilitation facility, home hospice) 5. Persistently impaired cognition as a result of illness (Impairment defined as ≥3 errors on the Callahan cognitive status screen and/or the lack of decisional capacity (i.e., patient could be consented by medical team for a procedure if necessary) 6. Currently imprisoned or incarcerated or in home detention 7. Lack a reliable smartphone with cellular data plan or access to the internet 8. Currently enrolled in another study involving an intervention whose objectives conflict with the objectives of this study 9. Previously enrolled in the trial Exclusion criteria present after hospital discharge (i.e., at T1 Data Collection conducted at the time of arrival home from the hospital) 1. Failure to randomize within 14 days from planned start date (planned start date is within 3 days post-discharge from the hospital to home to accommodate weekends) 2. Readmission to hospital before randomization completed
Conditions PreDiabetes
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Fasting hyperglycemia contributes disproportionately to nonenzymatic glycosylation and the microvascular complications of type 2 diabetes. However, little is known about the regulation of glucose concentrations in the fasting state relative to what is known about the postprandial state. The proposed experiment is part of a series of experiments designed to establish how glucagon and insulin interact with their receptors to control fasting glucose in health and in prediabetes.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Other: Intralipid and heparin — Intralipid (20%, 0.011ml/kg/min; Baxter, Healthcare, Deerfield, IL) and heparin (200 units prime, 0.2 unit/kg/min continuous) will be infused to induce acute insulin resistance
  • Other: Saline — Saline will be infused

Primary Outcomes

  • Suppression of Endogenous glucose production (EGP) by insulin (The rate of EGP at 240 minutes (end of study) expressed as a percentage of fasting EGP (at the start of the study i.e.: 0 minutes.)
  • Insulin pulse orderliness (Approximate Entropy (ApEn) will be calculated from the insulin concentrations observed every 2 minutes between -45 and 0 minutes)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-09-15
Completion: 2027-09-01
Eligibility
Age: 25 Years and older
Sex: ALL
Volunteers: true
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mayo Clinic
Principal Investigators:
  • Adrian Vella, MD (PRINCIPAL_INVESTIGATOR) - Mayo Clinic
Contact Information
Study Contact:
Kim Osmundson, CCRP
507-255-0907
Osmundson.Kimberly@mayo.edu
Jeanette Laugen
507-255-8110
Laugen.Jeanette@mayo.edu
Interventions
  • Other: Intralipid and heparin — Intralipid (20%, 0.011ml/kg/min; Baxter, Healthcare, Deerfield, IL) and heparin (200 units prime, 0.2 unit/kg/min continuous) will be infused to induce acute insulin resistance
  • Other: Saline — Saline will be infused
Study Locations (1 sites)
Mayo Clinic in Rochester, Rochester, Minnesota 55905 United States
Eligibility Criteria
Inclusion Criteria: * people with normal or impaired fasting glucose and normal or impaired glucose tolerance Exclusion Criteria: 1. HbA1c \> 6.5% 2. BMI ≥ 35 Kg/M2 3. Use of any glucose-lowering agents including metformin or sulfonylureas. 4. For female subjects: positive pregnancy test at the time of enrollment or study 5. History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy. 6. Active systemic illness or malignancy. 7. Symptomatic macrovascular or microvascular disease. 8. Hematocrit \< 35%
Conditions Hypertension, Diabetes, Postpartum, Preg...
Phase NA
Enrollment 1320
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The lack of postpartum primary care coordination is a missed opportunity to increase primary care engagement and manage chronic conditions early in life, especially for the \>30% of pregnant people who have or are at risk for these conditions. This study aims to increase postpartum primary care engagement, quality, and experience by strengthening postpartum transitions to primary care using a behavioral economics-informed, multi-component intervention integrated into usual inpatient postpartum care. Using a randomized controlled trial and repeated outcome assessments through administrative and survey data, this study will generate rigorous, actionable evidence to ensure primary care coordination becomes standard postpartum care practice, potentially catalyzing sustained primary care engagement throughout life.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: Triple

Interventions / Regimen

  • Other: Facilitated Transition to Primary Care — The intervention includes default PCP visit scheduling, tailored nudge messages to patients, ongoing care recommendations sent to the PCP, and a summary of recommendations after pregnancy given to the patient.

Primary Outcomes

  • Completion of a primary care visit (155 days after date of delivery)
  • Receipt of condition-specific recommended health screening and counseling by a primary care practitioner (155 days after date of delivery)
  • Self-report of having a known, reliable primary care practitioner (155 days after date of delivery)
  • Self-report of mental health (155 days after date of delivery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-23
Completion: 2028-05-23
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 1320 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Massachusetts General Hospital
Collaborators: Harvard School of Public Health (HSPH)
Principal Investigators:
  • Mark A Clapp, MD, MPH (PRINCIPAL_INVESTIGATOR) - Massachusetts General Hospital
Contact Information
Study Contact:
Mark A Clapp, MD, MPH
617-726-2000
mark.clapp@mgh.harvard.edu
Interventions
  • Other: Facilitated Transition to Primary Care — The intervention includes default PCP visit scheduling, tailored nudge messages to patients, ongoing care recommendations sent to the PCP, and a summary of recommendations after pregnancy given to the patient.
Study Locations (1 sites)
Massachusetts General Hospital, Boston, Massachusetts 02115 United States
Eligibility Criteria
Inclusion Criteria * Receiving obstetric care at an MGH-affiliated obstetrics practice (except for the MGH HOPE Clinic, which has a unique care model that provides prenatal and postnatal care for individuals with substance use disorder, including the provision of primary care through 2+ years postpartum) * Pregnant with a live fetus or delivered a live-born neonate ≥24 weeks of gestation, based on the clinical estimate of gestational age * If postpartum, has a neonate that is currently living at the time of enrollment * Has one or more of the following conditions listed in the "Problem List," "Medical History," or clinical notes during prenatal, intrapartum, or postpartum encounters in the EHR (or in the case of BMI, the patient's anthropometric measurements): * Chronic or essential hypertension * Hypertensive disorders related to pregnancy (e.g., pre-eclampsia) * Type 1 or 2 diabetes (i.e., pre-existing diabetes) * Gestational diabetes * Class II Obesity (pre-pregnancy body mass index ≥35 kg/m2; or if pre-pregnancy body mass index is not known, a first trimester BMI of ≥35 kg/m2) * Depression or anxiety disorder * Has a primary care clinician listed in the patient's medical record * Has access to or agrees to be enrolled in the electronic health record patient portal and consents to be contacted via these modalities * Able to read/speak English or Spanish language * Is age ≥18 years old Exclusion Criteria • Any individual not meeting all inclusion criteria
Conditions Breast Cancer
Phase PHASE2
Enrollment 53
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

1\. Efficacy of PULSAR preoperative radiation 2. Evaluate potential of microbubble CEUS as an alternative to operative SLNBx 3. Evaluate potential of OA to evaluate treatment response of pre-operative radiation on the tumor

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Radiomics on MRI — Through extracting and analyzing a large number of features from medical imaging, radiomics has shown promising results in treatment outcome prediction for many diseases including breast cancer (45-50). UTSW physics group has developed several new radiomic approaches and radiomic features, such as a multi-objective radiomics model(51) and a new radiomic "Shell" feature(52). As an exploratory end point for this trial, the investigators will explore the application radiomics using pre-treatment MRI, treatment parameters and clinical characteristics as input to predict pathological response of radiation therapy (XRT) based on pathology report of surgical tissues and local recurrence.
  • Drug: microbubble CEUS Contrast Enhanced Ultrasound (CEUS) — Microbubble Contrast non-FDA approved for route of administration

Primary Outcomes

  • Single fraction pre-operative radiation (4 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-10-11
Completion: 2028-07-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 53 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Texas Southwestern Medical Center
Principal Investigators:
  • Asal Rahimi, MD (PRINCIPAL_INVESTIGATOR) - University of Texas Southwestern Medical Center
Contact Information
Study Contact:
Sarah Neufeld, MS
214-645-8525
sarah.hardee@utsouthwestern.edu
Basak Dogan, MD
214/645-3290
Dogan.Basak@utsouthwestern.edu
Sarah Neufeld, MS
Sarah.Neufeld@utsouthwestern.edu
UT Southwestern Medical Center-Dallas
Interventions
  • Radiation: Radiomics on MRI — Through extracting and analyzing a large number of features from medical imaging, radiomics has shown promising results in treatment outcome prediction for many diseases including breast cancer (45-50). UTSW physics group has developed several new radiomic approaches and radiomic features, such as a multi-objective radiomics model(51) and a new radiomic "Shell" feature(52). As an exploratory end point for this trial, the investigators will explore the application radiomics using pre-treatment MRI, treatment parameters and clinical characteristics as input to predict pathological response of radiation therapy (XRT) based on pathology report of surgical tissues and local recurrence.
  • Drug: microbubble CEUS Contrast Enhanced Ultrasound (CEUS) — Microbubble Contrast non-FDA approved for route of administration
Study Locations (1 sites)
UT Southwestern Medical Center-Dallas, Dallas, Texas 75390 United States
Eligibility Criteria
Inclusion Criteria * Invasive epithelial (ductal, medullary, lobular, papillary, mucinous (colloid), or tubular) histologies of the breast 3 cm or less(T1-T2cN0) in women who have not undergone surgery or neoadjuvant endocrine or chemotherapy for current breast cancer diagnosis. It is recommended that these tumors are at least 1 cm for cohort 1 and less than 1 cm for cohort 2, however this is not required. * Tumor must not involve the overlying skin based on imaging evaluation and/or clinical exam * Age \>/= 18 years old and female * If the tumor is unifocal, greatest tumor dimension is 3cm or less based on imaging. Multifocal disease may be included if the aggregate span of disease is 3 cm or less, subject to investigator evaluation and approval. * The tumor must be visible on CTor MRI scan or preferably marked with clip(s) in tumor if not visible. * Patients must have undergone standard of care breast MRI or contrast-enhanced mammography for work up to aid in tumor delineation and to rule out multicentric disease. If areas suspicious of multicentric disease are seen which are beyond the scope of SBRT, they need to have a negative biopsy to proceed with treatment. * Clinically and radiographically node negative on ultrasound of the axilla or MRI on initial workup prior to microbubble contrast assessment (for cohort 1). * Estrogen receptor positive or Progesterone receptor positive and Her2neu negative Ability to understand and the willingness to sign a written informed consent. 10. Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control) prior to the start of study and for the duration of radiation therapy as well as the endocrine therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: * Has not undergone a hysterectomy or bilateral oophorectomy; or * Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months * For Cohort 1: If patient has had a prior biopsy clip placed in the lymph node deemed the sentinel lymph node at time of microbubble CEUS, it is up to investigator if additional biopsy and clip placement will be obtained. Exclusion Criteria * Multi-centric disease * Prior Radiation to the involved breast * Aggregate or single tumor Size \>3cm * Patients who are pregnant or lactating due to the potential exposure to the fetus to radiation therapy and unknown effects of radiation therapy to lactating females * Prior ipsilateral breast cancer * Patients with active lupus or scleroderma * Patients unable to have MRI or contrast-enhanced mammography per physician assessment. * For Cohort 1: If patient has a positive lymph node at time of microbubble contrast enhanced ultrasound, they will be removed from the study. Only cN0 patients to be treated on this study. Healthy Volunteer Inclusion Criteria * Ability to understand and the willingness to sign a written informed consent. * Age \>/= 18 years old and female * Without current diagnosis of breast cancer Healthy Volunteer Exclusion Criteria * Contraindication ot MRI * Volunteers who are pregnant
Conditions Depressive Disorder, Major, Persistent D...
Phase NA
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This two-armed randomized controlled trial aims to investigate the effectiveness of an emotion regulation intervention in individuals with and without depressive disorders. The study encompasses participants diagnosed with mild to moderate major depression or persistent depressive disorder and healthy controls without a current depressive disorder. Participants will be randomly assigned to either the intervention group, receiving a valence-specific emotion regulation intervention in daily life, or a monitoring-only control group. The valence-specific intervention supports the implementation of different emotion regulation strategies based on whether a person is experiencing mainly positive or negative emotions. In contrast, participants in the control group will solely monitor their positive and negative emotions and the strategies used to regulate them. Outcome measures include emotion regulation ability, self-efficacy, and strategy use, depressive symptoms, positive and negative affect, and emotion beliefs (controllability, usefulness). A second aim of the study is to compare beliefs about positive emotions and strategies to regulate them between individuals with and without current depressive disorders. Furthermore, the investigators aim to examine why individuals might choose unfavorable emotion regulation strategies even when feeling good. Therefore, another research question is, how emotion beliefs might explain emotion regulation strategy choice.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Valence-Specific Ecological Momentary Intervention — The ecological momentary intervention is designed to enhance participants ability to select and effectively implement emotion regulation strategies fitting to the valence of their current emotions. Specifically, the intervention instructs participants to use the strategy of savoring to amplify their positive emotions, fostering an appreciation for the present moment. Conversely, for the attenuation of negative emotions, the intervention advocates to use the strategy of reappraisal, encouraging participants to reinterpret adverse situations in a more positive or neutral way, thus reducing their emotional impact. This targeted approach ensures that the emotion regulation strategies are not only effective but also contextually appropriate.

Primary Outcomes

  • Emotion Regulation Ability (Positive, Negative Emotions) (0 weeks, 3 weeks)
  • Emotion Regulation Self-Efficacy for Positive and Negative Emotions (0 weeks, 3 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-01-12
Completion: 2025-08
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Heidelberg University
Principal Investigators:
  • Ilka Mueller, M.Sc. (PRINCIPAL_INVESTIGATOR) - Department of Psychology, Heidelberg University
  • Luise Pruessner, M.Sc. (PRINCIPAL_INVESTIGATOR) - Department of Psychology, Heidelberg University
  • Steffen Hartmann, M.Sc. (PRINCIPAL_INVESTIGATOR) - Department of Psychology, Heidelberg University
Contact Information
Study Contact:
Ilka Mueller, M.Sc.
+496221/547362
ilka.mueller@psychologie.uni-heidelberg.de
Luise Pruessner, M.Sc.
+496221/547282
luise.pruessner@psychologie.uni-heidelberg.de
Ilka Mueller, M.Sc.
+496221/547362
ilka.mueller@psychologie.uni-heidelberg.de
Department of Clinical Psychology and Psychotherapy, Institute of Psychology, Heidelberg University
Interventions
  • Behavioral: Valence-Specific Ecological Momentary Intervention — The ecological momentary intervention is designed to enhance participants ability to select and effectively implement emotion regulation strategies fitting to the valence of their current emotions. Specifically, the intervention instructs participants to use the strategy of savoring to amplify their positive emotions, fostering an appreciation for the present moment. Conversely, for the attenuation of negative emotions, the intervention advocates to use the strategy of reappraisal, encouraging participants to reinterpret adverse situations in a more positive or neutral way, thus reducing their emotional impact. This targeted approach ensures that the emotion regulation strategies are not only effective but also contextually appropriate.
Study Locations (1 sites)
Department of Clinical Psychology and Psychotherapy, Institute of Psychology, Heidelberg University, Heidelberg, 69117 Germany
Eligibility Criteria
Inclusion Criteria: * Online consent for participation * Adequate proficiency in the German language, encompassing both reading and comprehension skills * Ownership of a smartphone, compatible with either Android or iOS operating systems, and access to the Internet For individuals in the clinical group with current depressive disorders: * Currently meeting the DSM-5 criteria for a mild or moderate major depressive episode, or persistent depressive disorder Exclusion Criteria: * Current severe substance use disorder * Acute suicidality * Current severe major depressive episode * Lifetime bipolar disorder * Lifetime psychotic disorders For the control group, additional exclusion criteria include: * Meeting the DSM-5 criteria for a major depressive episode within the last 12 months * History of severe major depressive episodes * Recurrent depressive disorder * History of persistent depressive disorder * Current treatment (psychotherapy, pharmacotherapy) for depressive symptoms
Conditions Breast Cancer
Phase NA
Enrollment 31
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study evaluates the acute toxicity and feasibility of repeat breast conserving therapy with preoperative accelerated partial breast re-irradiation (PAPBI) in female patients aged 51 years or older with ipsilateral recurrent or second primary low-risk breast cancer or DCIS.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Preoperative accelerated partial breast irradiation — Patients will be treated with 5 x 5.2 Gray (Gy) preoperative accelerated partial breast irradiation of the in situ tumor in the breast
  • Procedure: Breast conserving surgery — Patients will be treated with breast conserving surgery.
  • Procedure: Sentinel node procedure — Patients will undergo a (repeat) sentinel node procedure.
  • Procedure: Biopsy track removal — The biopsy track will be surgically removed.

Primary Outcomes

  • Acute post-treatment toxicity (3,5 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-04-12
Completion: 2027-04-11
Eligibility
Age: 51 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 31 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Netherlands Cancer Institute
Collaborators: Medical Center Haaglanden, Erasmus Medical Center, Albert Schweitzer Hospital
Principal Investigators:
  • Astrid Scholten, MD PhD (PRINCIPAL_INVESTIGATOR) - The Netherlands Cancer Institute
Contact Information
Study Contact:
Tess Snellen, MD
0205129111
t.snellen@nki.nl
Lisa van den Hengel
0205129111
l.vd.hengel@nki.nl
Astrid Scholten, MD PhD
+31205129111
a.scholten@nki.nl
The Netherlands Cancer Institute
Interventions
  • Radiation: Preoperative accelerated partial breast irradiation — Patients will be treated with 5 x 5.2 Gray (Gy) preoperative accelerated partial breast irradiation of the in situ tumor in the breast
  • Procedure: Breast conserving surgery — Patients will be treated with breast conserving surgery.
  • Procedure: Sentinel node procedure — Patients will undergo a (repeat) sentinel node procedure.
  • Procedure: Biopsy track removal — The biopsy track will be surgically removed.
Study Locations (1 sites)
The Netherlands Cancer Institute, Amsterdam, 1066CX Netherlands
Eligibility Criteria
Inclusion Criteria: * Female patients ≥ 51 years * Ipsilateral breast cancer; recurrence or second primary * Either histologically proven invasive adenocarcinoma (invasive adenocarcinoma with DCIS component is also accepted) or DCIS alone (calcification associated on imaging) * Histologically proven estrogen receptor positive * HER2neu negative * In case of invasive adenocarcinoma: tumor size ≤ 3 cm. In case of DCIS alone: affected area ≤ 2.5 cm * Grade I or grade II (biopsy) * cN0M0 (No evidence of nodal or distant metastases on axillary ultrasound and, if indicated, positron emission tomography-computed tomography (PET-CT) scan) * Unifocal lesions on mammogram and MRI (small satellite lesions adjacent to the tumor are accepted as long as it is suitable for local excision) * Interval since completion of local treatment of primary tumor \> 12 months * Previous radiotherapy (whole breast or partial) of the ipsilateral breast * Repeat breast conserving surgery feasible * World Health Organization (WHO) performance ≤ 2 * Written informed consent * The patient is legally competent Exclusion Criteria: * ≥ grade 3 radiotherapy toxicity in the breast after treatment of the primary tumor * Previous boost radiotherapy is not allowed, UNLESS the protocol tumor lies outside of the original boost area * Distant metastases and/or synchronous contralateral invasive or in situ carcinoma * Invasive lobular carcinoma (ILC) or pleiomorphic lobular carcinoma in situ (LCIS) * ER negative subtype * Lymphovascular invasion in biopsy * Neoadjuvant systemic treatment for the protocol tumor (except for pre-surgery hormonal therapy ≤ 2 months) * (Planned) oncoplastic surgery with major tissue displacement * Participation in another clinical trial that interferes with the locoregional treatment of this protocol. * It is expected that dosimetric constraints cannot be met, such as lung/heart constraints. * Patients with proven BRCA-mutations

M3VAS Validation in Polish Population

NCT06412562
Recruiting
Conditions Depressive Disorder
Phase Not Applicable
Enrollment 150
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Low mood and anhedonia represent the fundamental symptoms of major depressive disorder (MDD). Nevertheless, there is currently no standardized visual analogue scale available to assess the extent of both symptoms concurrently. The Maudsley 3-item Visual Analogue Scale (M3VAS) is a newly developed tool for participants to self-assess core symptoms of depression: mood quality, pleasure experience (anhedonia), and suicidality. Despite suicidality not being a primary symptom, it is included due to its critical relevance to safety. Participants will be instructed to rate the intensity and frequency of their experiences over the preceding two weeks by marking a 100 mm ungraded line. A researcher will then assign a numerical value based on the mark's position, utilizing the left edge as 0 and the right as 100. The total score range, combining the three symptoms, ranged from 0 (minimum) to 300 (maximum). The M3VAS exhibited good psychometric properties in British population. In this study, the objective is to assess the psychometric properties of the scale within the Polish population diagnosed with major depressive episode within major depressive disorder or bipolar disorder.

Design

Study type: Observational Observational model: Cohort Time perspective: Cross Sectional

Interventions / Regimen

  • Diagnostic Test: The Maudsley 3-item Visual Analogue Scale (M3VAS) — Patients will be asked to complete The Maudsley 3-item Visual Analogue Scale (M3VAS) and 16-item Quick Inventory of Depressive Symptomatology (QIDS-SR-16).

Primary Outcomes

  • The Maudsley 3-item Visual Analogue Scale (M3VAS) (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-05-09
Completion: 2026-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical University of Gdansk
Collaborators: King's College London
Contact Information
Study Contact:
Alina Wilkowska, MD, PhD
+48 58 584 46 50
alina.wilkowska@gumed.edu.pl
Medical University of Gdańsk
Aleksander Kwaśny, MD
+48 58 584 46 50
Medical University of Gdańsk
Alina Wilkowska, MD, PhD
Medical University of Gdańsk
Interventions
  • Diagnostic Test: The Maudsley 3-item Visual Analogue Scale (M3VAS) — Patients will be asked to complete The Maudsley 3-item Visual Analogue Scale (M3VAS) and 16-item Quick Inventory of Depressive Symptomatology (QIDS-SR-16).
Study Locations (1 sites)
Medical University of Gdańsk, Gdansk, Poland
Eligibility Criteria
Inclusion Criteria: Diagnosis as provided by DSM-5 criteria: Major depressive disorder (MDD) Bipolar disorder (BD) Exclusion Criteria: Diagnosis as provided by DSM-5 criteria: Psychotic disorders Current Mania or hypomania within bipolar disorder (BD)
Conditions Electroacupuncture, Olanzapine-contained...
Phase PHASE3
Enrollment 370
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study explores the effectiveness of combining electroacupuncture with olanzapine-containing four-drug antiemetic therapy to mitigate chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer. The research aims to assess the adjunctive benefits of electroacupuncture in enhancing the antiemetic effects of conventional medication, particularly in the context of highly emetogenic chemotherapy regimens. By investigating the synergistic potential of these modalities, the study seeks to provide insights into optimizing supportive care strategies for patients with breast cancer undergoing intensive chemotherapy treatment.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Device: Electroacupuncture — Participants in this arm will undergo electroacupuncture sessions once daily from day 1 to day 4. Electrical stimulation will be administered for 30 minutes at alternating frequencies of 2/10Hz
  • Drug: Antiemetic Therapy — Participants will receive oral olanzapine at a dose of 5 mg per day on days 1 through 4, along with NK1 receptor antagonist, 5HT3 receptor antagonist, and intravenous dexamethasone at a dose of 10 mg 30 minutes prior to chemotherapy on Day 1, followed by intravenous dexamethasone at a dose of 8 mg on days 2, 3, and 4 post-chemotherapy.
  • Device: Sham electroacupuncture — Participants assigned to this arm will receive sham electroacupuncture sessions daily from day 1 to day 4, mirroring the schedule of the experimental group
  • Drug: Antiemetic Therapy — They will also receive the same antiemetic medications as the experimental group.

Primary Outcomes

  • Proportion of Patients Free from Nausea Throughout Treatment (120 hours)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-03-07
Completion: 2027-03-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 370 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Feixue Song
Contact Information
Study Contact:
Feixue Song, Dr
13639336037
13639336037@139.com
Feixue Song, Dr
13639336037
13639336037@139.com
Second Hospital of Lanzhou University
Interventions
  • Device: Electroacupuncture — Participants in this arm will undergo electroacupuncture sessions once daily from day 1 to day 4. Electrical stimulation will be administered for 30 minutes at alternating frequencies of 2/10Hz
  • Drug: Antiemetic Therapy — Participants will receive oral olanzapine at a dose of 5 mg per day on days 1 through 4, along with NK1 receptor antagonist, 5HT3 receptor antagonist, and intravenous dexamethasone at a dose of 10 mg 30 minutes prior to chemotherapy on Day 1, followed by intravenous dexamethasone at a dose of 8 mg on days 2, 3, and 4 post-chemotherapy.
  • Device: Sham electroacupuncture — Participants assigned to this arm will receive sham electroacupuncture sessions daily from day 1 to day 4, mirroring the schedule of the experimental group
  • Drug: Antiemetic Therapy — They will also receive the same antiemetic medications as the experimental group.
Study Locations (1 sites)
Second Hospital of Lanzhou University, Lanzhou, Gansu 730000 China
Eligibility Criteria
Inclusion Criteria: 1. Patients aged 18 to 75 years, inclusive, from any nationality. 2. Patients diagnosed with early-stage breast cancer. 3. Eastern Cooperative Oncology Group performance status ranging from 0 to 2. 4. All patients must undergo highly emetogenic chemotherapy (HEC). 5. Adequate organ function. 6. Adequate contraception required for premenopausal women. Exclusion Criteria: 1. Scheduled to undergo chemotherapy between days 2 to 4 following HEC. 2. Received or is planned to receive abdominal radiation therapy within 1 week before Day 1 in cycle 1. 3. Significant medical or psychological conditions. 4. Presents with symptomatic primary or metastatic central nervous system malignancy causing nausea and/or vomiting. 5. Experiencing ongoing vomiting or nausea of grade 2 or higher according to Common Terminology Criteria for Adverse Events (CTCAE). 6. Any known allergies to the study drug, antiemetics, or dexamethasone. 7. Patients who have fear of electroacupuncture stimulation or are allergic to stainless steel needles. 8. Received acupuncture treatments for any conditions within 8 weeks prior to HEC.
Conditions Triple Negative Breast Cancer
Phase PHASE2
Enrollment 85
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The primary purpose of this study is to determine what proportion of participants will achieve complete pathological response with epirubicin+ cyclophosphamide followed by docetaxel +carboplatin. This will also examine the potential of using signals in the blood (biomarkers) to identify resistance to chemotherapy in Nigerian women with triple negative breast cancer (TNBC). All enrollment to this trial will occur at sites in Nigeria. University of Chicago is serving as coordinating center and will be involved in data analysis.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Cyclophosphamide — Cyclophosphamide is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Epirubicin.
  • Drug: Epirubicin — Epirubicin is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Cyclophosphamide.
  • Drug: Docetaxel — Docetaxel is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Carboplatin. Dosing will start after treatment with Epirubicin and Cyclophosphamide (EC) is completed.
  • Drug: Carboplatin — Carboplatin is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Docetaxel. Dosing will start after treatment with EC is completed.
  • Procedure: Breast Surgery — Participants will undergo breast surgery after completing dosing with Carboplatin and Docetaxel to remove any remaining cancer in the breast.
  • Drug: Capecitabine — Capecitabine is a pill that will be taken by mouth daily for 6 months after surgery is completed.

Primary Outcomes

  • Percentage of Participants that Achieve Pathologic Complete Response (pCR) Rate (Breast) (4 - 6 months from start of chemotherapy)
  • Percentage of Participants that Achieve Pathologic Complete Response (pCR) Rate (Lymph Nodes) (4 - 6 months from start of chemotherapy)
  • Percentage of Participants that Achieve Pathologic Complete Response (pCR) Rate (By Stage) (4 - 6 months from start of chemotherapy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-03-18
Completion: 2032-06
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 85 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Chicago
Principal Investigators:
  • Olufunmilayo Olopade, MD (STUDY_CHAIR) - University of Chicago
Contact Information
Study Contact:
Ilona Siljander
773-834-6542
isiljander1@bsd.uchicago.edu
ABIODUN POPOOLA
+234 803 3021434
Lagos State University Teaching Hospital
ADEMOLA OYEKAN
+234 803 9277218
Lagos State University Teaching Hospital
Interventions
  • Drug: Cyclophosphamide — Cyclophosphamide is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Epirubicin.
  • Drug: Epirubicin — Epirubicin is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Cyclophosphamide.
  • Drug: Docetaxel — Docetaxel is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Carboplatin. Dosing will start after treatment with Epirubicin and Cyclophosphamide (EC) is completed.
  • Drug: Carboplatin — Carboplatin is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Docetaxel. Dosing will start after treatment with EC is completed.
  • Procedure: Breast Surgery — Participants will undergo breast surgery after completing dosing with Carboplatin and Docetaxel to remove any remaining cancer in the breast.
Study Locations (4 sites)
Lagos State University Teaching Hospital, Ikeja, Lagos 100271 Nigeria
Lagos University Teaching Hospital, Yaba, Lagos 100254 Nigeria
Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Osun State 220005 Nigeria
University of Ibadan Hospital, Ibadan, Oyo State 200285 Nigeria
Eligibility Criteria
Inclusion Criteria: 1. Women ages of 18 to 70 years old 2. Women who are able and willing to read understand and sign an informed consent document 3. Biopsy-accessible breast tumor of significant size for core needle biopsy/ultrasound measurable (≥ 2cm) 4. Patients with histologically confirmed carcinoma of the female breast with triple-negative status by immunohistochemistry (IHC). Patients who are low estrogen reception (ER) expression (\< 20%), progesterone receptor (PR) negative and human epidermal growth factor 2 (HER2) negative are eligible. 5. Clinical stages IIA -IIIC (AJCC 2009) 6. Chemotherapy-naïve patients (for this cancer) 7. Performance status: Eastern Cooperative Oncology Group (ECOG) performance status 0-1 8. Non-pregnant and not nursing. * Granulocyte greater than or equal to 1,500/microliter * Platelet count greater than or equal to 100,000/microliter * Absolute neutrophil count (ANC) greater than or equal to l500/microliter * Hemoglobin greater than or equal to 10g/deciliter * Bilirubin less than or equal 1.5 x upper limit of normal * aspartate aminotransferase (ALT or SGOT) and alanine transaminase (AST or SGPT) less than 2.5 x upper limit of normal 7\. Creatinine within institutional normal limits or glomerular filtration rate greater than or equal to 30 mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) equation 10. Baseline left ventricular ejection fraction of greater than or equal to 55% Exclusion Criteria: 1. Pregnant or lactating women. 2. Patients with distant metastasis (brain and/or visceral metastasis) 3. Serious, uncontrolled, concurrent infection(s). 4. Treatment for other carcinomas within the last 5 years, except non-melanoma skin cancer and treated cervical carcinoma in-situ (CCIS) 5. Participation in any investigational drug study within 4 weeks preceding the start of study treatment 6. Other serious uncontrolled medical conditions that the treating investigator feels might compromise study participation including but not limited to chronic or active infection, HIV-positive patient, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled diabetes mellitus, or psychiatric illness/social situations that would limit compliance with study requirements.